Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia : Development of a selective ?7 nicotinic acetylcholine receptor agonist strategy nAChR) in schizophrenia underlies impaired sensory inhibition, a possible endophenotype of the disorder. This ligand-gated ion channel receptor has been proposed as a pharmacotherapeutic target in schizophrenia. The current study examined the effect of CDP-choline alone and the combination of CDP-choline and galantamine, administered acutely and once-daily for five consecutive days, in an animal model of NMDA receptor hypofunction that is relevant to schizophrenia.
